0001213900-26-078373.txt : 20260715 0001213900-26-078373.hdr.sgml : 20260715 20260715170002 ACCESSION NUMBER: 0001213900-26-078373 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260715 DATE AS OF CHANGE: 20260715 EFFECTIVENESS DATE: 20260715 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cadrenal Therapeutics, Inc. CENTRAL INDEX KEY: 0001937993 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 880860746 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-590962 FILM NUMBER: 261177948 BUSINESS ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 306 CITY: PONTE VEDRA STATE: FL ZIP: 32082 BUSINESS PHONE: 904-300-0701 MAIL ADDRESS: STREET 1: 822 A1A NORTH STREET 2: SUITE 306 CITY: PONTE VEDRA STATE: FL ZIP: 32082 D 1 primary_doc.xml X0708 D LIVE 0001937993 Cadrenal Therapeutics, Inc. 822 A1A NORTH, SUITE 306 PONTE VEDRA FL FLORIDA 32082 (904) 300-0701 DELAWARE None None Corporation true 2022 Quang X. Pham 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Director Chairman of the Board and Chief Executive Officer John P. Sharp 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Interim Chief Financial Officer James J. Ferguson 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Chief Medical Officer Jeffrey S. Cole 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Executive Officer Chief Operating Officer Lee Golden 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director John R. Murphy 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32802 Director Glynn Wilson 822 A1A North, Suite 306 Ponte Vedra FL FLORIDA 32082 Director Biotechnology Decline to Disclose 06b false 2026-06-30 false true true false 0 H.C. Wainwright & Co., LLC 000000375 None None 430 Park Avenue New York NY NEW YORK 10022 NY NEW YORK false 8843849 8843849 0 The total offering amount reflects the total gross proceeds to be received assuming cashexercise of all warrants issued in the private placement. false 1 315000 true 0 The placement agent received a 7.0% cash fee of $210,000, 1.0% management fee of $30,000, non-accountable expenses of $25,000, accountable expenses of $50,000 and warrants to purchase 62,4000 shares of common stock. 0 true While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false Cadrenal Therapeutics, Inc. /s/ Quang X. Pham Quang X. Pham Chairman of the Board Chief Executive Officer 2026-07-15